The Human Variable 

CYNAERA’s AI simulations analyze 120+ therapeutic candidates across 6 mechanisms, weighting them by patient endotype, Pathos™ severity score, and predicted remission probability. This map provides the first public-facing mechanism reference, while full dosing logic, contraindication overlays, and trial-ready protocols remain licensed.

The CDF-Peds-ME/CFS™, developed by CYNAERA, is the first child-adapted Composite Diagnostic Fingerprint designed for school, home, and clinical settings. Built on CYNAERA’s validated CDF-ME framework, it integrates multi-system biomarkers, digital phenotyping, and school-based records into a practical, developmentally appropriate diagnostic solution.

CYNAERA’s PHAROS™ + REWIRE™ framework introduces a longitudinal, multi-pathway diagnostic system. By tracking cytokine rhythms over days, mapping vagal-histaminergic amplification, and integrating viral reactivation profiles, PHAROS™ + REWIRE™ replaces linear models with terrain-aware detection. This paper expands on the biological foundations of this model, critiques failed legacy approaches, and outlines a replicable path to mechanism-specific, real-world diagnostics.

ME/CFS is a relapsing, multisystem condition characterized by immune disruption, neuroinflammation, autonomic dysfunction, and energy metabolism abnormalities. Trials should anchor in stabilization before pursuing cure.

The Va-IRI™ (Vaccination Immune Readiness Index) provides a structured 0–100 readiness score derived from common labs, symptom baselines, and patient function. Built on the STAIR Stable Method™ (Stabilization, Tolerance, And Immune Readiness), Va-IRI™ adapts low-and-slow principles pioneered by patients and refined through collaboration with leading researchers.

Using CYNAERA’s US-CCUC™ (U.S. Chronic Condition Undercount Correction – Pediatric Edition) methodology, we estimate 1.5–3 million U.S. children and adolescents and 10–20 million globally meet ME/CFS criteria in 2025.